Curriculum Vitae

Dr. Jacobus J. Bosch, MD, PhD

Department of Medicine 5
Hematology and Medical Oncology
University Hospital Erlangen
91054 Erlangen, GERMANY
Tel. (+49)-9131-8545122
Fax. (+49)-9131-8536251
Email: jacobus.bosch@uk-erlangen.de

Scientific career

1995 – 2004 Study of Medicine, Leiden University, Leiden, The Netherlands.

1996 Propaedeutic exam Medicine, Leiden University, Leiden, The Netherlands.

1999 – 2000 Chairperson of the Board of the Medical Interfacultary Congress Foundation (M.I.C.), Utrecht, The Netherlands.

2000 Doctoral exam Medicine, Leiden University, Leiden, The Netherlands.

2000 – 2002 Pre-Doctoral Research Fellowship in Ocular-Immunology, The Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA.

2004 Doctor of Medicine (M.D.), Leiden University, Leiden, The Netherlands.

2005 – 2008 Post-Doctoral Research Fellowship in Tumor-Immunology, University of Maryland, Baltimore, Maryland, USA

2007 – 2010 Member of the Associate Member Council, American Association for Cancer Research, Philadelphia, PA, USA.

2009 – Present Member of the Medical Advisory Board of the Ocular Melanoma Foundation, Richmond, VA, USA

2009 – Present Resident and Research Group Leader in Hematology and Medical Oncology, University Hospital Erlangen, Erlangen, Germany

2012 Doctor of Philosophy (Ph.D). in Medicine, specifically Tumor-Immunology, Leiden University, Leiden, The Netherlands.
B.I.G. registration number: 19062838701 (NL Medical Doctor database)

2015- Principal Investigator of Project 4 “Tumor-associated lymphangiogenesis and its inhibition as a novel therapeutic strategy in conjunctival melanomas” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Medicine 5 Hematology and Medical Oncology at the University Hospital Erlangen

2018- Principal Investigator of Project P4 “The role of midkine in tumor-associated lymphangiogenesis and metastasis of ocular malignant melanoma” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Medicine 5 Hematology and Medical Oncology at the University Hospital Erlangen

Prizes and honors

2002 ARVO Research Travel Award: Association of Research in Vision and Ophthalmology, annual meeting; Joseph M. and Eula G. Lawrence Retina Research Foundation, Houston, TX, USA

2007 AACR – Aflac Inc. Scholar-in-Training Award, American Association for Cancer Research, annual meeting, Los Angeles, CA, USA

2010 OMF Junior Investigator Award, Ocular Melanoma Foundation, annual meeting, Boston, MA, USA

2000 – 2002 Research Scholarships of several scientific Foundations in the Netherlands

2006 – 2007 Post-Doctoral Research Stipend, Fight for Sight Inc., New York, NY, USA

Selected publications

Cursiefen C, Bock F, Clahsen T, Regenfuss B, Reis A, Steven P, Heindl LM, Bosch JJ, Hos D, Eming S, Grajewski R, Heiligenhaus A, Fauser S, Austin J, Langmann T. [New Therapeutic Approaches in Inflammatory Diseases of the Eye – Targeting Lymphangiogenesis and Cellular Immunity: Research Unit FOR 2240 Presents Itself]. Klin Monbl Augenheilkd. 2017 May;234(5):679-685.

Refaian N, Schlereth SL, Koch KR, Notara M, Hos D, Mescher M, Iden S, Bosch JJ, Jager MJ, Cursiefen C, Heindl LM. Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines. Invest Ophthalmol Vis Sci. 2015;56(9):5691-7

Gary R, Voelkl S, Palmisano R, Ullrich E, Bosch JJ, Mackensen A (2012) Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis. J Immunol. 188(2):744-52.

Bosch JJ (2012) Immunotherapy of uveal melanoma. Dev Ophthalmol. 49:137-49.

Haile ST*, Bosch JJ*, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S (2011) Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J Immunol. 186:6822-9. *these authors contributed equally

Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, Ksander BR, Ostrand-Rosenberg S (2010) Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8(+) cytotoxic, tumor-specific T cells. Cancer Immunol Immunother. 59:103-12.

Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S (2007) MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res. 67:4499-506.